Genomics player Illumina whacked with hefty patent case loss

A Washington court ruled against Illumina ($ILMN) in a patent lawsuit Thursday, finding that the sequencing giant infringed on Syntrix Biosystems' intellectual property and ordering the company to pay out $96 million in damages. The suit covers Illumina's BeadChip array, used in DNA and RNA analysis, which the court deemed to have infringed on Syntrix's similar technology. The $96 million figure is based on a royalty rate of 6% of BeadChip sales from 2005 to 2012. Illumina maintains that it did nothing wrong, however, and the company plans to file post-trial motions in an effort to vacate the court's decision. Item

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.